Thomas Ciulla MD PC

[ad_1] Pleased to co-edit the 2nd of 2 #genetherapy issues of International Ophthalmology Clinics: “DNA- and RNA-based Gene Therapies in Ophthalmology: Inherited and Noninherited Retinal Disorders” #eye #ophthalmology #retina #IRD #gene https://t.co/4N9toRLDTO [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Recently published, “Genes and Gene Therapy in Inherited Retinal Disease”. #eye #ophthalmology #retina #gene #genetherapy #Luxturna #IRD #clinicalresearch #clinicaltrials #drugdevelopment #biotech https://t.co/u17zTf9Oox [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @BauschSurgical: B+L and Clearside Biomedical announce the FDA approval of XIPERE™ which utilizes the suprachoroidal space to treat pati… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Looking forward to presenting on #suprachoroidal delivery at the Ophthalmology Innovation Source Drug Delivery Innovation Showcase! #eye #retina #drugdelivery #genetherapy #biotech https://t.co/QC85uDRp2f [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @OTEurope: XIPERE, the first therapy utilising the suprachoroidal space, demonstrates rapid efficacy, durable benefit and favourable saf… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @ThomasCiullaMD: Honored to have been interviewed by @retinapodcast on research, roles in industry, and innovations in retinal therapeut… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @AuraBiosciences: Aura is proud to share that Dr. Hakan Demirci’s scientific poster updating the safety data of the Phase 2 AU-011 trial… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.